Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Diphthine--ammonia ligase (DPH6) is an enzyme that catalyzes the last (amidation) step in the biosynthesis of diphthamide, a unique post-translationally modified histidine residue found in eukaryotic translation elongation factor 2 (eEF2)[2][3][5][7]. DPH6 uses ammonium and ATP to convert diphthine to diphthamide, a modification essential for normal translation and for the sensitivity of eEF2 to diphtheria toxin[1][6][7]. Loss of DPH6 function blocks diphthamide synthesis, causes accumulation of diphthine-modified eEF2, and can result in diphthamide deficiency syndromes[3]. The DPH6 protein is conserved in eukaryotes, contains an ATP-binding domain, and operates as part of the broader diphthamide biosynthesis pathway, which is critical for normal protein synthesis and cell viability[1][3][5][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Diphthine--ammonia ligase (DPH6).